The Wellness Company’s Chief Medical Board and the McCullough Foundation submitted for peer review a first-of-its-kind observational report of cancer patients who were prescribed compounded ivermectin + mebendazole through The Wellness Company’s licensed U.S. doctors.
In the 6-month follow-up group, 84.4% reported clinical benefit, meaning they reported no current evidence of disease, tumor shrinkage, or disease that stayed stable.
Among the 122 cancer patients who completed
6-month follow-up:
Reported clinical benefit.
Reported the strongest positive outcomes — either tumor shrinkage or no current evidence of disease.
Reported their disease stayed about the same.
Reported disease progression.
Go Deeper Into
The Wellness Company's Findings
The study began with 197 cancer patients, and 122 completed follow-up. Patients were prescribed capsules containing 25 mg ivermectin and 250 mg mebendazole. They took up to 4 capsules per day according to physician’s recommendation.
Real World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort
Self-reported cancer outcomes at 6-month follow-up (N=122)
For a medication that’s 1% the cost of chemotherapy, it showed a remarkable efficacy rate:
- 84.4% reported clinical benefit, defined as improvement or stabilization of disease.
- Nearly 1 in 2 reported the strongest positive outcomes: tumor shrinkage or no evidence of disease (NED).
- 15.6% reported progression of disease.
The protocol was a simple daily regimen of The Wellness Company’s compounded ivermectin (25mg) + mebendazole (250mg). These medications are theorized to disrupt tumor growth and cause cancer apoptosis (cell death). The protocol was easy for participants to follow:
- 86.9% completed their initial prescription.
- About two-thirds were still taking it at follow-up.
- Most people who reported side effects described them as mild and were still able to continue the protocol.
Ivermectin + Mebendazole:
An important tool in the battle against cancer
The exceptionally high self-reported Clinical Benefit Ratio (CBR) of 84.4% observed at the 6-month follow-up in this diverse real-world population is striking and underscores the potential clinical importance of the ivermectin and mebendazole combination.
Among other conventional cancer therapies – with surgery as the most common treatment reported in 83 participants (42.1%) - they also reported making diet and lifestyle changes like intermittent or prolonged fasting, ketogenic or low-sugar diets, hyperbaric oxygen, red-light therapy, and specific supplements (e.g., vitamin D, turmeric, berberine, mushrooms – all found in TWC’s SHIELD supplement).
This level of disease control (no evidence of disease, regression, or stability) substantially exceeds typical clinical benefit and disease control rates reported with standard chemotherapy in advanced or pretreated solid tumors.
Important note
The Wellness Company and The McCullough Foundation remain committed to investigating medicine’s unanswered questions and advancing our scientific knowledge.
Nicolas Hulscher, MPH1, 2*, Kelly Victory, MD2, James A. Thorp, MD2, Drew Pinsky, MD2, Alejandro Diaz-Villalobos, MD2, Peter Gillooly, MSc2, Foster Coulson, Melissa Annazone2, Chloe Radesi2, Jessica Brooks2, Peter A. McCullough, MD, MPH1, 2, Harvey Risch, MD, PhD2,3
The manuscript is currently undergoing peer review and is available as a preprint on Zenodo , a research repository operated by CERN (European Organization of Nuclear Research).